RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Scribed by Datko, F.M.; Dickler, M.N.

• Book ID: 122023335
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 295 KB
• Volume: 23
• Category: Article
• ISSN: 1043-321X
• DOI: 10.1016/j.breastdis.2012.10.001